Home Early-stage NSCLC Landscape: How the next decade looks like?

The landscape of advanced/metastatic NSCLC has changed dramatically with the approval of immunotherapies and targeted agents in recent years. After metastatic disease, early-stage NSCLC has become a new testing ground for these therapies. Most key players are in the race to position their drugs in this hitherto unexplored territory where surgery, radiotherapy (RT), or chemoradiation (ChemoRT) has remained the mainstay of treatment.

Let's together explore how early-stage NSCLC is shaping up with the entrenchment of new therapies and what new questions have emerged with this paradigm shift. FutureBridge’s Oncology Analysts in this webinar will cover . . .

Access the full-content and exclusive insights by registering to futurebridge.com.

Benefits to Registered User on FutureBridge

Explore Key trends

Stay on top of your industry related trends and oppotunities.

Access to exclusive content

Get insightful information access without any restrictions.

Trending topics

Learn about fundamental challenges confronted by your industry.

Unrestricted webinar access

Gain access to all upcoming webinars and reply on-demand.

Need a thought partner?

Share your focus area or question to engage with our Analysts through the Business Objectives service.

Submit My Business Objective

Our Clients

Our long-standing clients include some of the worlds leading brands and forward-thinking corporations.